image
Healthcare - Medical - Devices - NASDAQ - IL
$ 12.09
4.13 %
$ 228 M
Market Cap
54.95
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one BWAY stock under the worst case scenario is HIDDEN Compared to the current market price of 12.1 USD, BrainsWay Ltd. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one BWAY stock under the base case scenario is HIDDEN Compared to the current market price of 12.1 USD, BrainsWay Ltd. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one BWAY stock under the best case scenario is HIDDEN Compared to the current market price of 12.1 USD, BrainsWay Ltd. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BWAY

image
$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
41 M REVENUE
29.04%
1.39 M OPERATING INCOME
128.05%
2.92 M NET INCOME
169.60%
10.3 M OPERATING CASH FLOW
702.02%
30.3 M INVESTING CASH FLOW
181.03%
18.3 M FINANCING CASH FLOW
1880.02%
11.5 M REVENUE
1.07%
576 K OPERATING INCOME
33.64%
1.11 M NET INCOME
-28.49%
5.01 M OPERATING CASH FLOW
43.39%
-1.97 M INVESTING CASH FLOW
-6.67%
-755 K FINANCING CASH FLOW
-3.85%
Balance Sheet BrainsWay Ltd.
image
Current Assets 79.5 M
Cash & Short-Term Investments 69.3 M
Receivables 4.6 M
Other Current Assets 5.59 M
Non-Current Assets 14.6 M
Long-Term Investments 0
PP&E 11.9 M
Other Non-Current Assets 2.7 M
73.64 %4.88 %5.93 %12.69 %2.86 %Total Assets$94.2m
Current Liabilities 15.3 M
Accounts Payable 2.14 M
Short-Term Debt 1.65 M
Other Current Liabilities 11.6 M
Non-Current Liabilities 16.7 M
Long-Term Debt 4.8 M
Other Non-Current Liabilities 11.9 M
6.69 %5.14 %36.05 %14.98 %37.14 %Total Liabilities$32.0m
EFFICIENCY
Earnings Waterfall BrainsWay Ltd.
image
Revenue 41 M
Cost Of Revenue 10.4 M
Gross Profit 30.6 M
Operating Expenses 29.2 M
Operating Income 1.39 M
Other Expenses -1.53 M
Net Income 2.92 M
45m45m40m40m35m35m30m30m25m25m20m20m15m15m10m10m5m5m0041m(10m)31m(29m)1m2m3mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
74.56% GROSS MARGIN
74.56%
3.39% OPERATING MARGIN
3.39%
7.12% NET MARGIN
7.12%
4.69% ROE
4.69%
3.10% ROA
3.10%
1.47% ROIC
1.47%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis BrainsWay Ltd.
image
8m8m6m6m4m4m2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 2.92 M
Depreciation & Amortization 1.77 M
Capital Expenditures -3.79 M
Stock-Based Compensation 1.42 M
Change in Working Capital -12 K
Others 6.25 M
Free Cash Flow 6.5 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets BrainsWay Ltd.
image
Wall Street analysts predict an average 1-year price target for BWAY of $13.2 , with forecasts ranging from a low of $5 to a high of $16 .
BWAY Lowest Price Target Wall Street Target
5 USD -58.64%
BWAY Average Price Target Wall Street Target
13.2 USD 8.91%
BWAY Highest Price Target Wall Street Target
16 USD 32.34%
Price
Max Price Target
Min Price Target
Average Price Target
1616141412121010886644Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership BrainsWay Ltd.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Is the Options Market Predicting a Spike in Brainsway Stock? Investors need to pay close attention to Brainsway stock based on the movements in the options market lately. zacks.com - 1 month ago
Wall Street Analysts Believe Brainsway (BWAY) Could Rally 30.98%: Here's is How to Trade The mean of analysts' price targets for Brainsway (BWAY) points to a 31% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 1 month ago
Strength Seen in Brainsway (BWAY): Can Its 5.3% Jump Turn into More Strength? Brainsway (BWAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term. zacks.com - 1 month ago
Are Medical Stocks Lagging Brainsway (BWAY) This Year? Here is how Brainsway Ltd. Sponsored ADR (BWAY) and Cardinal Health (CAH) have performed compared to their sector so far this year. zacks.com - 1 month ago
Brainsway Ltd. Sponsored ADR (BWAY) Hits Fresh High: Is There Still Room to Run? Brainsway (BWAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com - 1 month ago
BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD) Improvement in depression scores, response and remission were all found to be comparable with standard Deep TMS in non-inferiority trial Improvement in depression scores, response and remission were all found to be comparable with standard Deep TMS in non-inferiority trial globenewswire.com - 1 month ago
Brainsway (BWAY) is on the Move, Here's Why the Trend Could be Sustainable Brainsway (BWAY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. zacks.com - 1 month ago
BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San Diego BURLINGTON, Mass. and JERUSALEM, June 10, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. globenewswire.com - 1 month ago
Does Brainsway (BWAY) Have the Potential to Rally 43.88% as Wall Street Analysts Expect? The mean of analysts' price targets for Brainsway (BWAY) points to a 43.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 1 month ago
BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC BrainsWay is actively evaluating similar investments in other leading U.S. mental health providers to raise awareness and expand access to transformative care BrainsWay is actively evaluating similar investments in other leading U.S. mental health providers to raise awareness and expand access to transformative care globenewswire.com - 1 month ago
Earnings Estimates Moving Higher for Brainsway (BWAY): Time to Buy? Brainsway (BWAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. zacks.com - 1 month ago
Wall Street Analysts See a 41.31% Upside in Brainsway (BWAY): Can the Stock Really Move This High? The average of price targets set by Wall Street analysts indicates a potential upside of 41.3% in Brainsway (BWAY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com - 2 months ago
8. Profile Summary

BrainsWay Ltd. BWAY

image
COUNTRY IL
INDUSTRY Medical - Devices
MARKET CAP $ 228 M
Dividend Yield 0.00%
Description Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Contact Bynet Building, Jerusalem, 9777518 https://www.brainsway.com
IPO Date April 17, 2019
Employees 120
Officers Prof. Abraham Zangen Ph.D. Co-Founder, Member of Scientific Advisory Board & Director Dr. Yiftach Roth Ph.D. Founder & Chief Scientific Officer Mr. Avner Hagai Founder & Director Mr. Ido Marom Chief Financial Officer Mr. Dor Hagai Vice President of Operations Dr. David Zacut M.D. Co-Founder & Vice-Chairman Mr. Michael Cohen Vice President of US Sales Mr. Gilead Moiseyev Ph.D. Chief Technology Officer Mr. Hadar Levy Chief Executive Officer Mr. Ross Mitchell Vice President of Global Marketing